Nature Communications (Sep 2022)
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
- Radia M. Johnson,
- Xueping Qu,
- Chu-Fang Lin,
- Ling-Yuh Huw,
- Avinashnarayan Venkatanarayan,
- Ethan Sokol,
- Fang-Shu Ou,
- Nnamdi Ihuegbu,
- Oliver A. Zill,
- Omar Kabbarah,
- Lisa Wang,
- Richard Bourgon,
- Felipe de Sousa e Melo,
- Chris Bolen,
- Anneleen Daemen,
- Alan P. Venook,
- Federico Innocenti,
- Heinz-Josef Lenz,
- Carlos Bais
Affiliations
- Radia M. Johnson
- Bioinformatics & Computational Biology, Genentech, Inc.
- Xueping Qu
- Oncology Biomarker Development, Genentech, Inc.
- Chu-Fang Lin
- Real World Data Science Analytics, Genentech, Inc.
- Ling-Yuh Huw
- Oncology Biomarker Development, Genentech, Inc.
- Avinashnarayan Venkatanarayan
- Discovery Oncology, Genentech, Inc.
- Ethan Sokol
- Cancer Genomics Research, Foundation Medicine, Inc.
- Fang-Shu Ou
- Alliance Statistics and Data Management Center, Mayo Clinic
- Nnamdi Ihuegbu
- Guardant Health, Inc
- Oliver A. Zill
- Bioinformatics & Computational Biology, Genentech, Inc.
- Omar Kabbarah
- Oncology Biomarker Development, Genentech, Inc.
- Lisa Wang
- Real World Data Science Analytics, Genentech, Inc.
- Richard Bourgon
- Bioinformatics & Computational Biology, Genentech, Inc.
- Felipe de Sousa e Melo
- Discovery Oncology, Genentech, Inc.
- Chris Bolen
- Bioinformatics & Computational Biology, Genentech, Inc.
- Anneleen Daemen
- Bioinformatics & Computational Biology, Genentech, Inc.
- Alan P. Venook
- University of California, San Francisco
- Federico Innocenti
- University of North Carolina at Chapel Hill
- Heinz-Josef Lenz
- USC Norris Comprehensive Cancer Center
- Carlos Bais
- Oncology Biomarker Development, Genentech, Inc.
- DOI
- https://doi.org/10.1038/s41467-022-33172-5
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic and acquired resistance to cetuximab treatment.
